## Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

Pacira Pharmaceuticals, Inc. Form 4 January 19, 2016 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading STACK DAVID M Issuer Symbol Pacira Pharmaceuticals, Inc. [PCRX] (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) \_X\_\_ Director 10% Owner X\_Officer (give title Other (specify C/O PACIRA 01/15/2016 below) below) PHARMACEUTICALS, INC., 5 CEO and Chairman SYLVAN WAY, SUITE 300 (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting PARSIPPANY, NJ 07054 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired 5. Amount of 6. 7. Nature of Security (Month/Day/Year) Execution Date, if Transaction(A) or Disposed of (D) Securities Ownership Indirect (Instr. 3) any Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial (Month/Day/Year) Owned Direct (D) Ownership (Instr. 8) Following or Indirect (Instr. 4) Reported  $(\mathbf{I})$ (A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) Code V Price (D) Amount Common 01/15/2016  $M^{(1)}$ \$ 1.61 15,285 <sup>(2)</sup> 15,000 A D Stock \$ Common 01/15/2016 S<sup>(1)</sup> 62.55 1,000 D 14,285 D Stock (3) \$ Common **S**<sup>(1)</sup> 63.69 01/15/2016 9.608 D 4.677 D Stock (4) 01/15/2016 S<sup>(1)</sup> \$ D Common 4,392 D 285 64.46 Stock

## Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

	(5)										
Common Stock							18,596	I	By Stack Schroon Mohawk FLP <u>(6)</u>		
Common Stock							1,208	I	By LCK Investmen LLC (7)	.t	
Reminder: R	Report on a sep	parate line for each cla				nd to the collection of ed in this form are not unless the form		SEC 1474 (9-02)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ative ities red (A) posed of 3, 4,	6. Date Exercisable and Expiration Date (Month/Day/Year)		(Instr. 3 and 4)		8 E S (1
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 1.61	01/15/2016		М		15,000	<u>(8)</u>	09/02/2020	Common Stock	15,000	
Reporting Owners											
]	Reporting Owner Name / Address				Relationships						
			Directo	Director 10% Ow			Officer Other				
STACK DAVID M C/O PACIRA PHARMACEUTICALS, 5 SYLVAN WAY, SUITE 300 PARSIPPANY, NJ 07054			, INC. X	Х		CEO and Chairman					
Signa	tures										
/s/ James Scibetta, Attorney-in-Fact			01/19/2016								
**Signature of Reporting Person		Date									

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- (2) Includes 109 shares of common stock acquired under the issuer's employee stock purchase plan in December 2015.

(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$62.04 to \$62.88, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4 and 5.

- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$63.17 to \$64.15, inclusive.
- (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$64.17 to \$65.06, inclusive.
- (6) Mr. Stack is the general partner of Stack Schroon Mohawk FLP.
- (7) Mr. Stack and his wife are the owners of LCK Investment LLC.
- (8) The option vested as to 50% of the option shares on February 2, 2011, 19,377 option shares vested on February 3, 2011, and the remaining option shares vested in successive equal monthly installments for the subsequent 19 months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.